BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) by Bristol Myers Squibb is programmed death receptor-1-directed antibody interactions [moa]. First approved in 2024.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDIVO QVANTIG is a subcutaneous formulation combining nivolumab (a PD-1 checkpoint inhibitor) with hyaluronidase to enable rapid subcutaneous delivery of this immuno-oncology agent. It works by blocking programmed death receptor-1 interactions, enabling T-cell activation against tumors. This fixed-dose combination represents a patient convenience innovation over intravenous nivolumab.
Growth
Early-stage growth product with nascent commercial infrastructure; small linked job count (1) suggests team ramping and early positioning opportunities.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig
Started Aug 2025
200 enrolled
Cancer
Why This Matters for Your Career
Worked on OPDIVO QVANTIG at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.